NAFLD as a Metabolic Disease: the Role of Lifestyle Modification and Interventions

Saturday, May 9, 2020

1:30 PM – 2:30 PM

Participants should be aware of the following financial/non-financial relationships:
Christos Mantzoros, MD: Ansh : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); coherus : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Ownership Interest (Status: Ongoing), Research Grant (Status: Ongoing), Shareholder (Status: Ongoing), Stockholder/Ownership Interest (excluding diversified mutual funds) (Status: Ongoing); Novo Nordisk : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 10/1/2019), Grant/Research Support (Status: Terminated --- 10/1/2019), Honorarium (Status: Terminated --- 10/1/2019), Research Grant (Status: Terminated --- 10/1/2019)

Learning Objectives:

Discuss the prevalence of NAFLD
Understand the pathogenesis of NAFLD
Understand the role of lifestyle modification and interventions in the treatment of NAFLD

Speaker(s)

Christos Mantzoros, MD

Professor
Harvard

Disclosure: Ansh : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); coherus : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Ownership Interest (Status: Ongoing), Research Grant (Status: Ongoing), Shareholder (Status: Ongoing), Stockholder/Ownership Interest (excluding diversified mutual funds) (Status: Ongoing); Novo Nordisk : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 10/1/2019), Grant/Research Support (Status: Terminated --- 10/1/2019), Honorarium (Status: Terminated --- 10/1/2019), Research Grant (Status: Terminated --- 10/1/2019)